David A Johnson

Title: Innovations of David A Johnson

Introduction

David A Johnson is a notable inventor based in Carmel, IN (US). He has made significant contributions to the field of biotechnology, particularly in the development of novel therapeutic agents. With a total of 3 patents to his name, Johnson's work has the potential to impact cancer treatment and diagnosis.

Latest Patents

One of Johnson's latest patents involves monoclonal antibodies that are reactive with a cell-surface glycoprotein. This invention relates to a novel tumor-associated antigen that is a cell-surface glycoprotein with a molecular weight ranging from 110,000 to 140,000 daltons. This antigen is present in various carcinomas, including squamous cell carcinomas and adenocarcinomas. The patent also includes antibodies that react with the antigen, hybridoma cell lines that produce these antibodies, and methods for utilizing the antibodies in cancer diagnosis and treatment. Another significant patent focuses on cytotoxic drug conjugates. These conjugates combine antibodies with cytotoxic methotrexate drugs, utilizing simple organic groups as linkers. The link to the antibody is an acyl group, while the link to the drug is an alkylidene hydrazide.

Career Highlights

David A Johnson is currently associated with Eli Lilly and Company, a leading pharmaceutical firm. His work at Eli Lilly has allowed him to further his research and development efforts in the field of cancer therapeutics.

Collaborations

Throughout his career, Johnson has collaborated with notable colleagues, including Bennett C Laguzza and William Leonard Scott. These collaborations have contributed to the advancement of his research and the successful development of his patents.

Conclusion

David A Johnson's innovative work in biotechnology, particularly in cancer treatment, showcases his dedication to improving medical outcomes. His patents reflect a commitment to advancing therapeutic options for patients facing cancer.